Dr. Reddy’s Lab (DRRD) delivered 4QFY24 revenue in line with our estimate.However, EBITDA was lower than expected due to higher SGA expenses andR&D spending. In addition to US generics/branded generics segments, DRRD isenhancing its offering through JVs/partnerships/acquisitions in nutraceuticals,vaccine, women’s health and dietary supplement space.